Financing ·
Silexion Therapeutics lowers Series E warrant exercise price to $0.2603, generating $0.84M in gross proceeds
SLXNSilexion Therapeutics Corp
Silexion Therapeutics Corp entered into an inducement offer on September 28, 2026, allowing holders of 3,216,928 Series E warrants to exercise at a reduced price of $0.2603 per share, generating approximately $0.84 million in gross proceeds. In exchange, the company issued new Series F and Series G warrants for up to 6,433,856 shares at the same exercise price. The company also lowered the exercise price for all remaining outstanding Series E warrants (3,846,161 shares) to $0.2603 per share. H.C. Wainwright & Co., LLC served as placement agent, receiving 7% cash fees and warrants for 225,185 shares. The transaction is expected to close on September 29, 2026. Silexion Therapeutics Corp operates in the biotechnology industry, focusing on drug discovery.